AzTrials
AzTrials

Polycystic Ovary SyndromePhase 3NCT02491333

The RCT of Acupuncture on PCOS Combined With IR

A Phase 3 study testing true acupuncture and metformin in people with Polycystic Ovary Syndrome and Insulin Resistance, run by The First Affiliated Hospital of Guangzhou Medical University at 1 site in China.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The objectives of this randomized controlled trial are to compare insulin sensitivity following true acupuncture + placebo metformin (Group 1) vs sham acupuncture + placebo metformin (Group 2) vs sham acupuncture + metformin (Group 3) in women with PCOS and IR. Read more about this study

Who is it for?
Ages 18 to 40 years, women only
Conditions the study is for
Polycystic Ovary Syndrome, Insulin Resistance
What is being tested?
true acupuncture and metformin
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
342 participants
Where
1 siteChina
Study dates
Aug 2015to Oct 2018
Phase
Phase 3
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 40 years
  • Women only
  • No healthy volunteers
  • Adult

Who may be able to join

  • Chinese women aged from 18 to 40 years.
  • BMI ≥18.5kg/m2.
  • Confirmed diagnosis of PCOS according to modified Rotterdam criteria in 2003 including at least two of the following three features: ①Oligo-(an intermenstrual interval >35 days or <8 cycles in the past year), amenorrhea (an intermenstrual interval>90 days) and/or; ② polycystic ovarian morphology, i.e. presence of >12 antral follicles (≤ 9mm) and/or ovarian volume >10 ml on transvaginal scanning and/or; ③clinical and/or biochemical hyperandrogenism. Clinical hyperandrogenism in China Mainland is defined as a Ferriman-Gallwey (FG) score ≥5 ; biochemical hyperandrogenism is total testosterone (T) > 2.6 nmol/l and free testosterone ≥6.0 pg/ml.
  • Presence of IR as defined by the homeostatic model assessment (HOMA-IR: [fasting insulin (μU/mL) × fasting glucose (mmol/L)] / 22.5). A value ≥ 2.14 will be considered to be indicative of IR.
  • No immediate fertility wish and willingness to use barrier methods to contraception for one year.
  • Willingness to sign the consent form.

Who cannot join

  • Exclusion of other endocrine disorders:
  • ① Uncorrected thyroid disease (defined as TSH < 0.2 mIU/mL or >5.5 mIU/mL). A normal level within the last year is adequate for entry.
  • ② Poorly controlled of Type I or Type II diabetes (defined as a HbA1c level > 7.0%), or patients receiving antidiabetic medications such as insulin, thiazolidinediones, acarbose, or sulfonylureas likely to confound the effects of study medication; Patients currently receiving metformin XR (extended release) for a diagnosis of Type I or Type II diabetes or for PCOS are alsoexcluded.
  • Cushing's syndrome (define as an archetype of MetS. High glucocorticoid levels lead to muscle, liver and adipocyte insulin resistance. 17-OHCS>55umol/24h or UFC>304nmol/24h) ④ Congenital adrenal hyperplasia (define as patients with known 21-hydroxylase deficiency or other enzyme deficiency leading to the phenotype of congenital adrenal hyperplasia. 17-OHP>10 ng/ml in ACTH 1-24 h excited test (after 60 min)) ⑤ Suspected androgen secreting adrenal or ovarian tumor.
  • Use of hormonal or other medication including Chinese Herbal prescriptions which may affect the outcome the last 2 months.
  • Receiving acupuncture in the past 2 months.
Show all 15Show fewer
  • Within 6 weeks pregnancy.
  • Post-abortion or postpartum within the past 6 weeks.
  • Breastfeeding within the last 4 months.
  • Not willing to give written consent to the study.
  • Having a bariatric surgery procedure within the past 12 months or being in a period of acute weight loss.
  • Additional exclusion criteria including:
  • Patients on oral contraceptives, depot progestins, or hormonal implants (including Implanon). A two month washout period will be required prior to screening for patients on these agents. Longer washouts may be necessary for certain depot contraceptive forms or implants, especially where the implants are still in place. A one-month washout will be required for patients on oral cyclic progestins.
  • Heart disease ③ Patients with a history of, or suspected cervical carcinoma, endometrial carcinoma, or breast carcinoma.
  • Patients enrolled into other studies that require medications. ⑤ Patients taking longer than a one month break during the protocol should not be enrolled.

Trial locations and contacts

1 site in 1 country.

China1 site
  • The First Affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, 510120

Other trials in China

About this study

Official title: The Effect of Acupuncture on Insulin Sensitivity of Women With Polycystic Ovary Syndrome and Insulin Resistance: a Randomized Controlled Trial

The objectives of this randomized controlled trial are to compare insulin sensitivity following true acupuncture + placebo metformin (Group 1) vs sham acupuncture + placebo metformin (Group 2) vs sham acupuncture + metformin (Group 3) in women with PCOS and IR.

Read the detailed description

1.1 Study design This is a randomized double blind controlled. 1.2 Subject selection and exclusion Women with PCOS and IR will be recruited from the Department of Traditional Chinese Medicine in the first affiliated hospital of Guangzhou Medical University, Xuzhou maternity \& child health hospital, Liwan hospital of traditional Chinese medicine, and Hexian memorial affiliated hospital of Southern Medical University if they meet the inclusion criteria and do not have any exclusion criteria. Eligible subjects will be approached and sign the consent form after detailed explanation of the study design and comprehensive counseling.

1.3 Screening visit Women will be screened in the morning after an overnight 12 hour fast. Detailed information about the study design will be given.

1.3.1 Sign informed consent Informed consent will be signed after detailed counseling. 1.3.2 Perform physical examination Perform complete physical examination including height, weight, hip, and waist measurement. Height and weight will be recorded to the nearest 0.1 cm and 0.1 kg respectively. Waist and hip circumference will be recorded to the nearest 1 cm. And assessment of hirsutism by FG, acne standard acne lesion counts, and pelvic exam.

1.3.3 Perform transvaginal ultrasound of ovaries Ovaries, including the ovarian size in three dimensions, the size of the largest ovarian follicle/cyst and size of every follicle with a mean diameter greater than 10 mm, and total antral follicle count (small follicles with mean diameter < 10 mm) of each ovary will be obtained through transvaginal ultrasound.

1.3.4 Check urine pregnancy test 1.3.5 Fasting blood samples to exclude other endocrine disorders Fasting (at least 4 h) blood samples will be taken to exclude any endocrine disorders:F-glucose, F-insulin, Hba1C (>7%), C-peptide, TSH (< 0.2 mIU/mL or >5.5 mIU/mL), T3 (<1.4 nmol/L or >2.2nmol/L), and free T4 (<10pmol/L or >23pmol/L).

1.3.6 Progestin withdrawal Prescribe progestin to induce withdrawal bleed, after eligibility is determined.

1.4 Baseline visit After screening visit, if a woman fulfills inclusion criteria and has signed the informed consent she will be assigned to the baseline visit. Baseline visit takes place day 2 - 5 of a spontaneous period or after a withdrawal bleeding after an overnight fast.

1.4.1 Laboratory Examination Collect 20ml of blood, and 10ml of blood will be for the following tests. The remaining 10ml of blood will be stored for determination of DNA and sphingolipid later.

  1. Circulating sex steroids: Fasting serum levels of follicle-stimulating hormone (FSH), luteinizing hormone (LH), estrogen (E2), prolactin (PRL) and T, sex hormone binding globulin (SHBG), and dehydroepiandrosterone sulfate (DHEAS).
  2. Lipid profile: Triglycerides (TG), total cholesterol (TC), high density lipoprotein (HDL-C), low density lipoprotein (LDL-C), apolipoprotein A1 (Apoa1), apolipoprotein B (ApoB), BRT, Renal, and Liver Profile.
  3. Glucose homeostasis: The oral glucose tolerance test (OGTT) with 75 g glucose. Blood samples will be obtained to measure plasma glucose, serum insulin and C-peptide at 0, 60, and 120 min during the OGTT.

1.4.2 Complete questionnaires Quality of life will be assessed by the short form 36(SF-36), the Chinese Quality of Life (ChiQOL), sleeping questionnaires, international physical activity questionnaire (IPAQ) and the Polycystic Ovary Syndrome Questionnaire (PCOS-QOL). Investigators will also assess symptoms of anxiety and depression by the Zung SAS and Zung SDS questionnaires. And complete the quantization table of traditional Chinese medicine (TCM) syndromes about PCOS.

1.4.3 Assess TCM syndromes of patients Syndrome differentiation (Bian Zheng) in TCM is the comprehensive analysis of clinical information gained by the four main diagnostic TCM procedures: observation, listening, questioning, and pulse analysis, and it is used to guide the choice of treatment either by acupuncture and/or TCM herbal formulae. In PCOS, patients are empirically differentiated to be four categories: 1) phlegm-dampness syndrome, 2) blood stasis syndrome, 3) phlegm, and 4) blood stasis.

  1. Intervention arms 2.1 Information to all study subjects All participants will be advised about the importance of regular physical exercise and a balanced diet by a trained dietician. Importantly, they will be instructed not to change their exercise or diet habits during the entire study period.

True acupuncture or, sham acupuncture and metformin/placebo will be started 2 days after the baseline visit including OGTT. All subjects will be asked to use a barrier method for contraception. True and sham acupuncture treatment will be given three times per week. Each treatment session lasts for 30 minutes and can be separated by an interval of 1-3 days, with a maximum of 90 treatment sessions during 4 month. After the third treatment, all patients fill in the expectation and credibility questionnaire. Metformin or placebo will be given at 0.5g/times, 3 times one day and for 4 month.

2.1.1 True acupuncture protocol The rationale of acupuncture protocols is based on Western Medical theories and the study protocol follows the CONSORT and STRICTA recommendations.Investigators will use fixed acupuncture protocols. The acupuncture protocol of this RCT follows the protocol in the following studies: ClinicalTrial.gov NCT01457209 and NCT02026323.

Disposable, single-use, sterilized needles made of stainless steel, 0.25 x 30 mm and 0.30 x 40/50 mm (Hwoto, Suzhou Medical Appliance Fact. 215005 Suzhou, China) will be inserted to a depth of 15-35 mm in segmental acupuncture points located in abdominal and leg muscles with innervations corresponding to the ovaries. Two sets of acupuncture points will be alternated every second treatment. The first set consists of conception vessel (CV) 4, CV 12, and stomach (ST) 29 bilaterally and in the muscles above the knee, ST 34, and ST 32 bilaterally and below the knee, spleen (SP) 6 and ST 36. Needles will also be placed in extra segmental acupuncture points that do not innervate the ovaries large intestine (LI) 4 bilaterally. In total 14 needles will be placed and all will be stimulated manually by rotating the needle to evoke needle sensation (de qi) once when inserted. The following points will be connected to an electrical stimulator (Export Abteilung, Schwa-Medico GmbH,Wetzlarer Str. 41-43;35630 Ehringshausen): CV 4 to CV 12, ST 29 bilateral, ST34 to ST 32 bilateral. Stimulation are given as low-frequency EA of 2Hz, 0.3 ms pulse length and with an intensity adjusted to produce local muscle contractions without pain or discomfort. Needles not connected to the electrical stimulator will be manually stimulated to evoke needle sensation every 10 min, in total 4 times. The second set consists of 14 needles placed in segmental abdominal points and stimulated electrically: ST 27 bilaterally, CV6 connected to CV10; and leg points: SP10 connected to a non-acupuncture point located 6 cun proximal of patellas medial border (electrical stimulation), and SP 6 and liver (LR) 3 bilaterally (manual stimulation). Extra segmental points are pericardium (PC) 6 bilaterally (manual stimulation).

2.1.2 Needle insertion technique Needle insertion should be gentle. Tighten the skin by pressing around the area of needle insertion and gently insert the needle.

2.1.3 Needles and stimulation Needle size: 0.25 x 30 mm or 0.30 x 40 or 0.30 x 50 mm. Select needle length with respect to the patients'BMI: 0.25 x 30 mm needles in women with normal BMI; 0.30 x 40 mm needles in overweight women and 0.30 x 50 or 75 mm needles in obese women. Depth of insertion may vary from patients to patients. Needles are placed with a depth deep enough to reach muscle/fibrous tissue. When needle are inserted, stimulate the needle gently until de qi (needle sensation reflecting activation of sensory afferents). As soon as de qi has been reached, make sure that the needle does not hurt or cause any pain and discomfort. Manual stimulation of needles that is not attached to an electrical stimulator (see below) are stimulated when inserted, after 10 minutes, 20 minutes and immediately before they are removed after 30 minutes.

Attach the electrodes according to the protocol. Turn on the stimulator (program 10) and increase the intensity. The intensity will be as high as possible without pain or discomfort. The stimulation amplitude/intensity will be adjusted after 10 and 20 minutes at the same time as when needle stimulated manually are manipulated. After 30 minutes the stimulator is turned off, electrodes disconnected and needles taken out.

2.1.4 Sham acupuncture protocol Disposable, single-use, sterilized needles made of stainless steel, 0.20 x 20 mm (Hwoto, Suzhou Medical Appliance Fact.215005 Suzhou, China) will be inserted superficially to a depth of <5 mm, one in each shoulder and on in each upper arm at non-acupuncture points. Placement of needles is unlikely to affect ovulation and IR in women with PCOS. Electrodes will be attached to the needles and the stimulator will be turned on at an intensity of zero (no active current) in order to mimic EA in the acupuncture protocol. No manual stimulation of the needles will be performed. An intended adjustment of the intensity after 10 minutes, 20 minutes and again after 30 minutes when stimulator is turned off and needles removed.

2.1.5 True and sham acupuncture treatment

  1. Time of the day and acupuncturist name when the patient receives acupuncture will be recorded.
  2. The intensity of stimulation (mA) is noted. It may vary between different electrodes. Note the range e.g. 1.2 - 3.0 mA.
  3. Note any other events that may affect the treatment (positive or negative).
  4. Note concomitant medications.
  5. Collect menstrual logs at the end of every cycle. 2.2 Metformin and placebo Metformin (Kombiglyze XR) and placebo metformin will be packed and tested by a commercial pharmacy supply company (Squibb Company, Shanghai, China) specifically for this study. Metformin or placebo will be started 2 days after baseline visit including OGTT. Subjects will take 0.5 g/times, 3 times one day for up to 6 cycles.

2.3 Monitoring and examination during the treatment Physical examination will be performed monthly. Every menstruation should be recorded, including the date, volume and duration of menstruation during the entire study and follow-up. The condition of physical exercise and diet will be recorded for every cycle. OGTT will be repeated in the third month during the treatment.

2.4 End of treatment visit

During the end of treatment visit will all baseline measures be repeated as listed below:

  1. Perform physical examination, including vital signs, height, weight, hip and waist measurements as well as repeating hirsutism and acne assessments after the end of treatment or pregnancy.
  2. Repeat the serum levels of sex hormone steroids and metabolic profile.
  3. Repeat transvaginal ultrasound of ovarian morphology.
  4. Repeat OGTT.
  5. Collect 20ml blood, and distributed store 10ml blood after serum separation. Other 10ml blood is for determination of DNA and sphingolipid.
  6. Repeat QOL, sleeping, IPAQ anxiety/depression questionnaires, and the quantization table of TCM.
  7. Collect menstrual logs.
  8. Record adverse events and concomitant medications.
  9. Answer the two questions about acupuncture treatment. 2.5 Follow-up visit Baseline and end of treatment visit will be repeated 3 months after last treatment (see point 1-8 under End of treatment visit). All the participants will be followed up with visiting the acupuncturists monthly for 3 month. The condition of physical exercise and diet will be record every month.

2.6 Safety analysis Adverse events will be categorized and percentage of patients experiencing adverse events and serious adverse events during the treatment period and follow up period will be documented. Chi-square tests will be performed to examine differences in the proportion of total and categories of adverse events.

2.7 Statistics One sample of the Kolmogorov-Smirnov test will be used to test the normal distribution of continuous variables. Continuous variables will be presented as means ± standard deviations if they are normally distributed or as medians with interquartile ranges if they are not normally distributed. Statistical comparison will be carried out according to the intention to treat by Student's t-test, Mann-Whitney U-test, and Wilcoxon signed ranks test for continuous variables and by χ2 tests for categorical variables where appropriate. All statistical analyses of the data will be performed using the SPSS program version 21.0 (SPSS Inc., Chicago, IL, USA), and a P-value < 0.05 will be considered statistically significant.

Being tested
true acupuncture, sham acupuncture, metformin, Placebo metformin
Keywords
polycystic ovary syndrome, acupuncture, insulin resistance, HOMA-IR, metformin
Medical subject headings
Polycystic Ovary Syndrome, Insulin Resistance

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • true acupunctureOther

    True acupuncture treatment will be given three times per week. Each treatment session lasts for 30 minutes and can be separated by an interval of 1-3 days, with a maximum of 48 treatment sessions during 4 month.

  • sham acupunctureOther

    Sham acupuncture treatment will be given three times per week. Each treatment session lasts for 30 minutes and can be separated by an interval of 1-3 days, with a maximum of 48 treatment sessions during 4 month.

  • metforminDrug

    Also called Dimethylbiguanide

    Metformin will be given at 0.5g/times, 3 times one day and for 4 month.

  • Placebo metforminDrug

    Also called placebo Dimethylbiguanide

    Placebo metformin will be given at 0.5g/times, 3 times one day and for 4 month.

Study groups in NCT02491333
Study groupRoleWhat they receive
true acupuncture + placebo metforminExperimentalTrue acupuncture and placebo metformin will be started 2 days after the baseline visit including OGTT. All subjects will be asked to use a barrier method for contraception. True acupuncture treatment will be given three times per week. Each treatment session lasts for 30 minutes and can be separated by an interval of 1-3 days, with a maximum of 48 treatment sessions during 4 month. Placebo metformin will be given at 0.5g/times, 3 times one day and for 4 month.
Receives: Other: true acupuncture; Drug: Placebo metformin
sham acupuncture + placebo metforminSham comparatorSham acupuncture and placebo metformin will be started 2 days after the baseline visit including OGTT. All subjects will be asked to use a barrier method for contraception. Sham acupuncture treatment will be given three times per week. Each treatment session lasts for 30 minutes and can be separated by an interval of 1-3 days, with a maximum of 48 treatment sessions during 4 month. Placement of needles is unlikely to affect ovulation and IR in women with PCOS. Placebo metformin will be given at 0.5g/times, 3 times one day and for 4 month.
Receives: Other: sham acupuncture; Drug: Placebo metformin
sham acupuncture + metforminActive comparatorSham acupuncture and metformin will be started 2 days after the baseline visit including OGTT. All subjects will be asked to use a barrier method for contraception. Sham acupuncture treatment will be given three times per week. Each treatment session lasts for 30 minutes and can be separated by an interval of 1-3 days, with a maximum of 48 treatment sessions during 4 month.Placement of needles is unlikely to affect ovulation and IR in women with PCOS. Metformin will be given at 0.5g/times, 3 times one day and for 4 month.
Receives: Other: sham acupuncture; Drug: metformin

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Changes of HOMA-IR

    Measured: Change from Baseline Systolic Blood Pressure at 4 months and 7 months

Secondary outcomes (11)
  1. HOMA-B

    Measured: 4 months and 7 months

  2. AUCglu

    Measured: 4 months and 7 months

  3. Menstrual frequency

    Measured: 4 months and 7 months

  4. Body composition(a composite)

    Weight, BMI, waist-to-hip circumference, FG and acne lesion counts

    Measured: 4 months and 7 months

  5. Metabolic profile(a composite)

    Glucose and insulin concentrations, C-peptide, HbA1c, TC, TG, HDL-C and LDL-C, ApoA1 and ApoB.

    Measured: 4 months and 7 months

  6. Hormonal profile(a composite)

    FSH, LH, T, SHBG and DHEAS

    Measured: 4 months and 7 months

  7. Questionnaires(a composite)

    SF-36, ChiQOL, sleeping questionnaires, IPAQ, PCOS-QOL, Zung SAS, Zung SDS questionnaires and the quantization table of TCM syndromes about PCOS

    Measured: 4 months and 7 months

  8. Side effect profile

    Measured: 4 months and 7 months

  9. Expectation and credibility of treatment(questionnaire, 6 questions,4grades,0-24scores)

    Measured: 1 week and 4 months

  10. AUCins

    Measured: 4 months and 7 months

  11. Ovulation rate

    Measured: 4 months and 7 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 Jul 2015 (estimated)
  2. Study startAug 2015
  3. Primary completionOct 2018
  4. Study completionOct 2018

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
342 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02491333
Sponsor's protocol ID
PCOSIRct
Status last verified
Mar 2022
First submitted
24 Jun 2015
Last updated
21 Mar 2022
Results posted
No
Data monitoring committee
Yes

Publications

  • Lakkakula BV, Thangavelu M, Godla UR. Genetic variants associated with insulin signaling and glucose homeostasis in the pathogenesis of insulin resistance in polycystic ovary syndrome: a systematic review. J Assist Reprod Genet. 2013 Jul;30(7):883-95. doi: 10.1007/s10815-013-0030-1. Epub 2013 Jun 22.

    PubMed 23794114
  • Nestler JE. Role of hyperinsulinemia in the pathogenesis of the polycystic ovary syndrome, and its clinical implications. Semin Reprod Endocrinol. 1997 May;15(2):111-22. doi: 10.1055/s-2007-1016294.

    PubMed 9165656
  • Farrell K, Antoni MH. Insulin resistance, obesity, inflammation, and depression in polycystic ovary syndrome: biobehavioral mechanisms and interventions. Fertil Steril. 2010 Oct;94(5):1565-74. doi: 10.1016/j.fertnstert.2010.03.081. Epub 2010 May 14.

    PubMed 20471009
  • Bhathena RK. Insulin resistance and the long-term consequences of polycystic ovary syndrome. J Obstet Gynaecol. 2011;31(2):105-10. doi: 10.3109/01443615.2010.539722.

    PubMed 21281021
  • Hernandez-Valencia M, Hernandez-Rosas M, Zarate A. [Care of insulin resistance in polycystic ovary syndrome]. Ginecol Obstet Mex. 2010 Nov;78(11):612-6. Spanish.

    PubMed 21298999
  • Franks S. When should an insulin sensitizing agent be used in the treatment of polycystic ovary syndrome? Clin Endocrinol (Oxf). 2011 Feb;74(2):148-51. doi: 10.1111/j.1365-2265.2010.03934.x.

    PubMed 21121941
  • Pauli JM, Raja-Khan N, Wu X, Legro RS. Current perspectives of insulin resistance and polycystic ovary syndrome. Diabet Med. 2011 Dec;28(12):1445-54. doi: 10.1111/j.1464-5491.2011.03460.x.

    PubMed 21950959
  • Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001 Oct;108(8):1167-74. doi: 10.1172/JCI13505.

    PubMed 11602624
  • Hwang KR, Choi YM, Kim JJ, Chae SJ, Park KE, Jeon HW, Ku SY, Kim SH, Kim JG, Moon SY. Effects of insulin-sensitizing agents and insulin resistance in women with polycystic ovary syndrome. Clin Exp Reprod Med. 2013 Jun;40(2):100-5. doi: 10.5653/cerm.2013.40.2.100. Epub 2013 Jun 30.

    PubMed 23875167
  • Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R, Welt CK; Endocrine Society. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013 Dec;98(12):4565-92. doi: 10.1210/jc.2013-2350. Epub 2013 Oct 22.

    PubMed 24151290
  • Chang CT, Chen YC, Fang JT, Huang CC. Metformin-associated lactic acidosis: case reports and literature review. J Nephrol. 2002 Jul-Aug;15(4):398-402.

    PubMed 12243370
  • Triggle CR, Ding H. Cardiovascular impact of drugs used in the treatment of diabetes. Ther Adv Chronic Dis. 2014 Nov;5(6):245-68. doi: 10.1177/2040622314546125.

    PubMed 25364492
  • Dunaif A. Drug insight: insulin-sensitizing drugs in the treatment of polycystic ovary syndrome--a reappraisal. Nat Clin Pract Endocrinol Metab. 2008 May;4(5):272-83. doi: 10.1038/ncpendmet0787. Epub 2008 Mar 25.

    PubMed 18364705
  • Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, Ali F, Sholley C, Worrall C, Kelman JA. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA. 2010 Jul 28;304(4):411-8. doi: 10.1001/jama.2010.920. Epub 2010 Jun 28.

    PubMed 20584880
  • Mamtani R, Haynes K, Bilker WB, Vaughn DJ, Strom BL, Glanz K, Lewis JD. Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study. J Natl Cancer Inst. 2012 Sep 19;104(18):1411-21. doi: 10.1093/jnci/djs328. Epub 2012 Aug 9.

    PubMed 22878886

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing true acupuncture and metformin in people with Polycystic Ovary Syndrome and Insulin Resistance, run by The First Affiliated Hospital of Guangzhou Medical University at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 21 Mar 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Changes of HOMA-IR (time frame: Change from Baseline Systolic Blood Pressure at 4 months and 7 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02491333, which also lists 39 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Mar 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in